The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Checkpoint blocking antibodies in cancer immunotherapy
Open accessAbstract
Cancers can be recognized by the immune system, and the immune system may regulate and even eliminate tumors. The development of checkpoint blocking antibodies, such as those directed against cytotoxic T‐lymphocyte antigen 4 (CTLA‐4) and programmed death 1 receptor (PD‐1), have demonstrated significant recent promise in the treatment of an expanding list of malignancies. While both CTLA‐4 and PD‐1 function as negative regulators, each plays a non‐redundant role in modulating immune responses. CTLA‐4 attenuates the early activation of naïve and memory T cells. In contrast, PD‐1 is primarily involved in modulating T cell activity in peripheral tissues via interaction with its ligands, PD‐L1 and PD‐L2. Unfortunately, not all patients respond to these therapies, and evaluation of biomarkers associated with clinical outcomes is ongoing. This review will examine the efficacy, toxicities, and clinical development of checkpoint blocking antibodies, including agents already approved by the US Food and Drug Administration (anti‐CTLA‐4, ipilimumab) or in development (anti‐PD‐1, PD‐L1). Future studies will likely uncover new promising immunologic checkpoints to target alone or in combination with other immunotherapeutic approaches, chemotherapy, radiotherapy, and small molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“BMS-936559 was tested in a dose escalation phase I/II study in pretreated patients with a variety of malignancies including NSCLC, melanoma, CRC, RCC, ovarian cancer, pancreatic cancer, and breast cancer [62].”
BackgroundFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“Together, these findings suggest that interrupting the PD-1:PD-L1/PD-L2 interaction could be an effective anticancer therapy by blunting inhibition of immune responses in the tumor microenvironment [54,55].”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Cited by
T-cell exhaustion in the tumor microenvironment
Jiang, Y., Li, Y., & Zhu, B. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.162 · Cited by 1,157
Patterns of metastasis in colon and rectal cancer
Riihimäki, M., Hemminki, A., Sundquist, J., & Hemminki, K. (2016) · Scientific Reports · doi:10.1038/srep29765 · Cited by 947
He, C., Duan, X., Guo, N., Chan, C., Poon, C., Weichselbaum, R. R., & Lin, W. (2016) · Nature Communications · doi:10.1038/ncomms12499 · Cited by 754
Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3321 · Cited by 605
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590
Metastatic spread in patients with gastric cancer
Riihimäki, M., Hemminki, A., Sundquist, K., Sundquist, J., & Hemminki, K. (2016) · Oncotarget · doi:10.18632/oncotarget.10740 · Cited by 462
Immunosuppression associated with chronic inflammation in the tumor microenvironment
Wang, D., & DuBois, R. N. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv123 · Cited by 355
Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape
Garg, A. D., Coulie, P. G., Van den Eynde, B. J., & Agostinis, P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.006 · Cited by 340
Verma, V., Shrimali, R. K., Ahmad, S., Dai, W., Wang, H., Lu, S., Nandre, R., Gaur, P., Lopez, J., Sade-Feldman, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0441-y · Cited by 333
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 328
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
Guerriero, J. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.006 · Cited by 293
Co-delivery of chemotherapeutics and proteins for synergistic therapy
He, C., Tang, Z., Tian, H., & Chen, X. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.021 · Cited by 231
Cierna, Z., Mego, M., Miskovska, V., Machalekova, K., Chovanec, M., Svetlovska, D., Hainova, K., Rejlekova, K., Macak, D., Spanik, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv574 · Cited by 162
Impact of the spheroid model complexity on drug response
Hoffmann, O. I., Ilmberger, C., Magosch, S., Joka, M., Jauch, K.-W., & Mayer, B. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.02.029 · Cited by 125
Immune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Svetlovska, D., Kalavska, K., Rejlekova, K., Spanik, S., Kajo, K., Babal, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15585 · Cited by 79
“PD-L1 and PDL2 are ligands primarily involved in modulating T cell activity in peripheral tissues through interaction with PD-1 receptor [15].”
BackgroundTertiary lymphoid structures associate with tumour stage in urothelial bladder cancer
Koti, M., Xu, A. S., Ren, K. Y. M., Visram, K., Ren, R., Berman, D. M., & Siemens, D. R. (2017) · Bladder Cancer · doi:10.3233/blc-170120 · Cited by 78
Probiotic species in the modulation of the anticancer immune response
Marinelli, L., Tenore, G. C., & Novellino, E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.007 · Cited by 64
Metadata
- Authors
- Kyi, C., & Postow, M. A.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2013-10-23
- Volume
- 588
- Issue
- 2
- Pages
- 368-376
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2069592230
- Cited by
- 249
- References
- 27
- FWCI
- 15.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.